Our Pipeline

Diverse pipeline of innate cell engagers designed to activate innate immunity

A number of clinical and preclinical programs are in development based on the ROCK® platform and our tetravalent bispecific immune cell engagers have already shown a favorable safety profile and promising signs of therapeutic efficacy.

Innate Cell Engagers

AFM13

Disease Target CD30Immune Cell Target CD16A
Hodgkin lymphoma + PD-1
Phase 1
Hodgkin lymphoma
Phase 2
CD30+ lymphoma + adoptive NK cells
Pre-IND
CD30+ lymphoma
Phase 2

AFM24

Disease Target EGFRwtImmune Cell Target CD16A
Solid tumors
Pre-IND

AFM26

Disease Target BCMAImmune Cell Target CD16A
Multiple Myeloma
Pre-IND
Affimed programs
Partnered programs

We use cookies to give you the best experience on our website. By continuing to use it, you agree with it.

Okay